Clinical Trial Update: Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008) [Phase 3]

View source ↗

Summary

Phase 3 safety and efficacy study of ceftolozane/tazobactam for ventilated nosocomial pneumonia has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Healthcare-associated Pneumonia
• Ventilator-associated Pneumonia

Drugs mentioned

• Ceftolozane/Tazobactam (ceftolozane/tazobactam)

Snippet

Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Healthcare-Associated Pneumonia, Ventilator-Associated Pneumonia | Phase 3 | Status: COMPLETED | Results posted: 2019-05-31